CatalYm GmbH’s Post

Discover the buzz from #ASCO24!   Our latest analysis dives deep into the 42K+ tweets from this year's ASCO Annual Meeting, showcasing the buzzing conversations around monoclonal antibodies, drug targets, and small molecules. With over 230M impressions and 2M engagements, ASCO's digital engagement is at an all-time high. 𝗞𝗲𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: - 86% of tweets from individual oncologists or industry professionals - Top trending cancer topics: Lung, Breast, and Hematologic Cancer Explore the insights and see how conversations are shaping the future of oncology. Check out our flyer to see the detailed breakdown and trending topics that captivated the ASCO audience. #Oncology #ASCO2024 #CancerResearch #ProcDNAInsights #MedicalData #ProcDNA

As #CancerImmunotherapyMonth comes to a close, we remain committed to discovering new approaches to cancer immunotherapy that open the door to potential novel treatments for patients in need. At Arcus, we have focused on building exceptional small molecule, medicinal chemistry and antibody capabilities to optimize the combinability of molecules within our portfolio. Learn from our President Juan Jaen and CMO Dimitry Nuyten about how we are targeting the #adenosineaxis to harness the body’s own immune system to attack and destroy #coloncancer: https://bit.ly/3VbWzJg

Interested in discussing the latest advances in DNA damage response inhibition? Then, come and meet us at the ESMO - European Society for Medical Oncology Congress 2024, starting today in Barcelona! You will find our team presenting the following posters: 💊 Debio 0123 + Carboplatin for Patients with Advanced Solid Tumors: Safety, Preliminary Efficacy and Determination of Recommended Phase 2 Dose (Saturday, September 14th from 9 AM - 5 PM) 👨⚕️ Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin and etoposide in patients with small cell lung cancer that progressed after  platinum-based therapy: a phase 1 dose escalation and expansion study (Saturday, September 14th from 9 AM - 5 PM) 🔬 Anti-Tumor Effect of Debio 0432, A Potent and Selective USP1 Inhibitor in Combination with PARP Inhibitors (Sunday, September 15th from 9 AM - 5 PM) #cancer #oncology #research #clinicaltrials

A recently published study by Merck KGaA, Darmstadt, Germany, EMD Serono, Inc., Christian-Albrechts-Universität zu Kiel, and Technische Universität Darmstadt investigates bispecific NK cell-engaging antibodies (NKCEs) for cancer immunotherapy, focusing on the impact of antibody architecture on their efficacy. ✅ It highlights the importance of design, valency, and NKp30 epitope recognition in influencing NKCE characteristics. ✅ The research emphasizes the benefits of Fc domains for prolonged half-life and demonstrates that the tested NKCEs exhibit IgG-like pharmacokinetic profiles, indicating their clinical potential in cancer treatment. ✅ For simultaneous binding experiments as well as kinetic measurements the Octet®️ BLI technology was used. Read the study here: https://ow.ly/mzfO50RE5fG #AntibodyEngineering #ProteinEngineering #Antibodies #DrugDevelopment #EpitopeMapping #OctetBLI

👩⚕️ One of the biggest challenges in oncology is resistance. 1 in 2 people will be diagnosed with cancer in their lifetime, and over 90 % of cancer deaths are caused by drug resistance, one of the biggest unmet medical needs in the field of cancer. 👨⚕️   🎯 At Heidelberg Pharma AG the patient is the focus of all our efforts! Our amanitin-based ADC pipeline is designed to overcome resistance. 🎯 📌 Learn more about our patient-focused approach by watching our R&D webinar: https://lnkd.in/eVJygzyn   #ADCs #ATAC #CancerResearch

Immuno-oncology – activating the immune system to fight #cancer – has been revolutionary for treating blood cancer. However most solid tumors still lack effective #immunotherapy. SOTIO is focused on developing new treatments for solid tumors, with 3 programs in clinical trials. #Immune2Cancer #CancerResearch #biotechnology #jsmePPF

The Pfizer, Pfizer Boulder Research Unit, and academic collaborators' clinical and translational work on PF-07799933 (ARRY-440) is out in the September issue of Cancer Discovery. A next-generation, brain-penetrant, pan-mutant BRAF-selective inhibitor, together with innovative and accelerated phase 1 clinical development with demonstrated efficacy in treatment-refractory cancer patients. https://lnkd.in/gmQKJkNz

Join CEO, David Regan, CMO Dr carman giacomantonio, and CSO Len Pagliaro for an exclusive webinar tomorrow at 3 pm EDT for a discussion about Sona’s melanoma data from its current preclinical efficacy study of Sona's innovative cancer treatment therapy, Targeted Hyperthermia Therapy (THT). This is your opportunity to discover how Sona's THT therapy, when paired with conventional immunotherapies, could revolutionize certain cancer treatment outcomes. Register here: https://bit.ly/3RClyTW #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

In November 2023, our CMO, Dr. Qasim Iftikhar Ahmad, participated in Drug Discovery World's Turning Science into Business Summit, focusing on 'cancer research opportunities and advances' and 'cutting-edge concepts and tools in cancer drug discovery'.   During his presentation, Dr. Ahmad delved into IO Biotech's novel immunotherapy approach and its lead investigational therapeutic cancer vaccine candidate, IO102-IO103, with a dual mechanism of action designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment, which is currently being evaluated in a pivotal Phase 3 study for the first line treatment of patients with advanced #melanoma.   Read more on page 10 in Drug Discovery World's Winter 2023/2024 issue here: bit.ly/3S6FA8A.

Introducing CLSI MM26: Cancer Molecular Testing: Principles of Oncology Test Interpretation, Laboratory and Assay Design, and Clinical Consultation, 1st Edition. CLSI MM26 focuses on strategies for use of effective communication and consultation channels with clinicians in addition to test utilization management to support improved diagnosis, treatment selection, and risk assessment to guide care for patients with cancer. Download it here >> https://ow.ly/jiQE50SFbWi.